Propanc Biopharma, Inc.
PPCB
$1.87
-$0.08-4.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2,398.21% | 33.02% | 23.81% | 31.57% | 21.56% |
| Total Depreciation and Amortization | -4.17% | -8.93% | -2.65% | -4.80% | 0.47% |
| Total Amortization of Deferred Charges | -22.73% | -7.43% | 16.76% | 44.90% | 93.48% |
| Total Other Non-Cash Items | 10,478.36% | -71.69% | -58.18% | -82.23% | -29.31% |
| Change in Net Operating Assets | -23.59% | 41.83% | -21.87% | -11.66% | -10.62% |
| Cash from Operations | 25.22% | 35.89% | 9.92% | 15.38% | 36.24% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 0.68% | -20.10% | 6.29% | 79.87% | 15.03% |
| Total Debt Repaid | 25.54% | 31.14% | 100.00% | -- | -- |
| Issuance of Common Stock | -89.20% | -91.60% | -93.84% | -95.59% | -83.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -7.18% | -38.30% | -16.77% | -15.44% | -43.03% |
| Foreign Exchange rate Adjustments | -107.66% | -1,774.29% | 161.28% | 272.00% | 72.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 151.26% | -220.55% | 121.26% | 85.00% | -114.29% |